CGEN Quote, Financials, Valuation and Earnings

Can-Fite BioPharma Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of --. Compugen Ltd.'s return on equity of -51.8% beat Can-Fite BioPharma Ltd.'s return on equity of --.

Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 224.02%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1026.13%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Compugen Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Compugen Ltd..

Compugen Ltd. has a beta of 2.864, which suggesting that the stock is 186.386% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.068, suggesting its more volatile than the S&P 500 by 6.818%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Compugen Ltd.'s net income of -$7M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 23.92x versus 24.77x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of -3470.71%. Compugen Ltd.'s return on equity of -51.8% beat Pluri, Inc.'s return on equity of -5662.45%.

Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 224.02%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 226.09%. Given that Pluri, Inc. has higher upside potential than Compugen Ltd., analysts believe Pluri, Inc. is more attractive than Compugen Ltd..

Compugen Ltd. has a beta of 2.864, which suggesting that the stock is 186.386% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.181%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are larger than Pluri, Inc. quarterly revenues of $198K. Compugen Ltd.'s net income of -$7M is lower than Pluri, Inc.'s net income of -$6.9M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 23.92x versus 22.48x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teva Pharmaceutical Industries Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of 10.16%. Compugen Ltd.'s return on equity of -51.8% beat Teva Pharmaceutical Industries Ltd.'s return on equity of 20.99%.

Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 224.02%. On the other hand Teva Pharmaceutical Industries Ltd. has an analysts' consensus of $38.05 which suggests that it could grow by 10.82%. Given that Compugen Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Compugen Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..

Compugen Ltd. has a beta of 2.864, which suggesting that the stock is 186.386% more volatile than S&P 500. In comparison Teva Pharmaceutical Industries Ltd. has a beta of 0.702, suggesting its less volatile than the S&P 500 by 29.764%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teva Pharmaceutical Industries Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Teva Pharmaceutical Industries Ltd. pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are smaller than Teva Pharmaceutical Industries Ltd. quarterly revenues of $4.8B. Compugen Ltd.'s net income of -$7M is lower than Teva Pharmaceutical Industries Ltd.'s net income of $483M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Teva Pharmaceutical Industries Ltd.'s PE ratio is 28.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 23.92x versus 2.30x for Teva Pharmaceutical Industries Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

XTL Biopharmaceuticals Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of -341.36%. Compugen Ltd.'s return on equity of -51.8% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.

Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 224.02%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 3273.44%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Compugen Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Compugen Ltd..

Compugen Ltd. has a beta of 2.864, which suggesting that the stock is 186.386% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.178, suggesting its more volatile than the S&P 500 by 17.838%.

Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.

Compugen Ltd. quarterly revenues are $1.9M, which are larger than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. Compugen Ltd.'s net income of -$7M is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 23.92x versus 15.82x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.